Pfizer leaps 13% on news that its COVID-19 vaccine is over 90% effective in preventing illness

Pfizer soared 13% in pre-market trading on Monday after announcing its coronavirus vaccine succeeded in final stage clinical trials.
The US drugmaker's vaccine is in development with German biotech firm BioNTech, whose shares soared 26%.
The vaccine won't be immediately available as it still needs to be reviewed by the US Food and Drug Administration.
Visit Business Insider's homepage for more stories.

Pfizer leapt 13% in pre-market trading on Monday after the drugmaker announced that its experimental COVID-19 vaccine succeeded in late-stage trials.

The US pharma firm said its vaccine, developed with German biotech partner BioNTech, is over 90% effective in preventing COVID-19 infection.

BioNTech's shares soared 26%.

More to follow

Read the original article on Business Insider

from Business Insider https://ift.tt/3lc9dUs

COVID-19 New Corona